NCT00212771View on ClinicalTrials.gov

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)

PHASE3CompletedINTERVENTIONAL

Enrollment

440

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

September 30, 2006

Study Completion Date

October 31, 2006

Conditions

SchizophreniaSchizoaffective Disorder

Interventions

DRUG

asenapine

Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.

DRUG

olanzapine

Flexible dose, 1-2 capsules oral once per day (in the morning). Each capsule contains 10 mg olanzapine or matching placebo.

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00212771 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846) | Biotech Hunter | Biotech Hunter